Skip to content

Educational content only. Not investment advice: no price targets or buy and sell recommendations of our own.

Learn biotech investing by following real catalysts.

Upcoming trial readouts and clinical pipelines for 7 biotech companies, taken from ClinicalTrials.gov and linked to plain explanations of what each milestone means.

Next catalysts

All 42
  1. Dec 2026
    Sickle Cell Trait · Recruiting · NCT06071377
  2. Dec 2026
    Beam Therapeutics · Phase 1/2?
    Lymphoblastic Lymphoma, T-Cell Lymphoblastic Leukemia/Lymphoma, Lymphoblastic Leukemia · Active, not recruiting · NCT05885464
  3. 19 May 2027
    Circio Holding ASA · Phase 1/2?
    Multiple Myeloma, Smoldering Multiple Myeloma · Recruiting · NCT05841550
  4. 6 Jun 2027
    Sickle Cell Disease, Hydroxyurea Failure, Hydroxyurea Intolerance · Active, not recruiting · NCT05329649
  5. 9 Jun 2027
    Beta-Thalassemia, Thalassemia, Hematologic Diseases · Recruiting · NCT05477563
  6. Jun 2027
    Cardiovascular, Metabolic Disease, Dyslipidemias · Recruiting · NCT07491172
  7. Jun 2027
    Pancreatic Ductal Adenocarcinoma, Refractory Non-Small Cell Lung Cancer · Active, not recruiting · NCT06015724
  8. Jul 2027
    Neuromuscular Disease, Neuromuscular Diseases (NMD), Neurodegenerative Disease · Recruiting · NCT06672237

Dates are the estimated primary completion dates reported to ClinicalTrials.gov. Results are often announced weeks or months later, and sponsors move dates. Data fetched 7 October 2026.

Companies

All companies